Nagiel Laboratory News

One family shares their journey with the groundbreaking gene therapy Luxturna, which helps restore vision loss caused by a rare retinal disease.

A national leader in pediatric gene therapy, CHLA has treated more patients with the sight-saving Luxturna than any other center in the country.

Originally training in ballet, Kayla Stepanian took on a role at CHLA and is now a Research Specialist working on research into inherited retinal diseases.

Since high school, Leila has been fascinated by how DNA molecules define our fundamental characteristics.

Sumitha is a postdoctoral fellow exploring a key event in retinal development: the formation of the first synapse in the visual system.

Dr. Nagiel is investigating retinal development—studying exactly how photoreceptors connect with bipolar cells, the next downstream cells in the system.

After being treated with a breakthrough gene therapy at Children’s Hospital Los Angeles for a genetic eye disorder, 5-year-old Natalia can now see clearly for the first time in her life.

Una cirugía avanzada que se realiza en solo 10 hospitales del país mejora considerablemente la visión de una niña de 5 años.

Amber Medina Clinical Research Coordinator Amber helps coordinate leukemia and lymphoma trials. Though she has been doing clinical research for 15 years, Amber came to CHLA just two years ago. Joining

Thanks to a groundbreaking treatment, children who once faced inevitable blindness now have a chance to regain—and retain—their sight.